Who we are
Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.
Neovii was founded following the acquisition of Fresenius Biotech inheriting more than three decades of experience in specialty pharmaceuticals.
What Neovii stands for
Neovii’s global headquarters are located in Rapperswil, Switzerland, and its biologics manufacturing site and German operations are located in Gräfelfing, Germany. Neovii employs approximately 150 employees and has a presence in nearly 60 countries worldwide.
1979ATG-Fresenius® S (now Grafalon®) is manufactured for the first time
1981First clinical use in organ transplantation
1989First clinical use of the ATG-Fresenius® S polyclonal antibody in stem cell transplantation
2010FDA grants orphan drug status and fast track designation for the development of ATG-Fresenius® S for prevention of GVHD in the United States
2011German Health Authorities (PEI) approves ATG-Fresenius® S for GVHD prophylaxis in stem cell transplantation in Germany
2013Fresenius Biotech becomes Neovii
2014Neovii global headquarters are established in Rapperswil, Switzerland
2015ATG-Fresenius® S is re-branded and launched as GRAFALON®.
We are inspired by the meaningful work we do and are passionately committed to success.
We are open-minded, implement creative solutions and encourage entrepreneurship.
We set clear, ambitious targets.
Neovii aspires to be a fully integrated global pharmaceutical company with several franchises focused on diseases with unmet needs. We continually support customers up and down the value chain and are always in pursuit of maximizing total patient care.
We believe that our competencies and strengths combined with our values and culture make Neovii an employer of choice.